Corflow – A combined diagnostic and therapeutic system for patients with microvascular obstruction (MVO).

CorFlow’s Controlled Flow Infusion (CoFI) System, which has been granted Breakthrough Device Designation by the FDA, diagnoses MVO immediately following primary percutaneous coronary intervention and delivers therapeutics locally to the obstructed microvasculature. MVO after an acute heart attack is documented to be an independent marker leading to costly complications such as Heart Failure. CorFlow may enable interventional cardiologists to treat MVO in severe heart attack patients thereby potentially reducing the short- and long-term complication rates in these patients.